sRNAlytics  is at the forefront of small RNA research. We offer technology and services to drug developers to facilitate therapeutic development by providing deep analysis of disease pathways within a drug’s mechanism of action. Our analytical approach and wet-lab protocols, combined with sRNA-FIND and a growing database of over 15,000 patient samples, is focused on accelerating our partners programs.

 

World Class Team

David W. Salzman, PhD
Founder and CEO

Neal Foster, MBA
CBO

Nathan Ray
CTO

Alan P. Salzman, PhD
COO

 
 
sRNAlyticsHeadShots_Sean2.png
 
 

Sean Melville, MSc
Director of Business Development

 
 

Scientific Advisory Board

Frank J. Slack, PhD
Harvard Medical School

Richard H. Myers, PhD
BU Medical School

Joanne B. Weidhaas, MD, PhD
UCLA Medical School

Melanie L. Leitner, PhD
Accelerating Neuro

 
 
 
 

Blair R. Leavitt, MDCM, FRCP
University of British Columbia

 
 

Legal Advisors

 

Peter B. Finn, Esq.
Rubin and Rudman

 

Mark L. Hayman, PhD, JD
Morgan Lewis

 

There is a pervasive need to create new medicines for the treatment of diseases, which drives scientific breakthroughs and advances technology.
Combining new types of data, algorithms and computing platforms empowers sRNAlytics to create, and invent.
Join us in our mission to solve meaningful problems and make the world a better place.